Publication: Quality of Life of Chronic Myeloid Leukemia Patients receiving Tyrosine Kinase Inhibitor (TKI): Comparison with Healthy Population
| creativeworkseries.issn | ISSN 3059-9156 (Print), ISSN 3059-9164 (Online) | |
| dc.contributor.author | Gautam, Ajaya Raj | |
| dc.contributor.author | Bhattarai, Stuti | |
| dc.date.accessioned | 2025-12-31T08:21:57Z | |
| dc.date.available | 2025-12-31T08:21:57Z | |
| dc.date.issued | 2024 | |
| dc.description | Ajaya Raj Gautam Department of Internal Medicine, Rapti Academy of Health Sciences, Ghorahi, Dang, Nepal. Stuti Bhattarai Research Department, Rapti Academy of Health Sciences, Ghorahi, Dang, Nepal. | |
| dc.description.abstract | Abstract: Introduction: Development of tyrosine kinase inhibitors (TKIs) has changed the therapeutic landscape of chronic myeloid leukemia (CML) patients with an improved 10 years’ survival rate approximately from 20% to 90%. So, Quality of life (QoL) is an aspect of CML disease management that is gaining prominence in recent years. In Patan Hospital also, an increased 10 years’ survival rate has been seen among CML patients receiving TKIs under Glivec International Patient Assistance Program (GIPAP). So, the aim of this study was to compare the QoL of CML patients under treatment in Patan Hospital with the apparently healthy population. Methods: This is a cross sectional comparative study done at Patan Academy of Health Sciences (PAHS) from October 2018 to September 2019. Short Form 36 (SF-36) questionnaire was used for QoL assessment. Ethical approval was obtained. Data analysis was done using epi info version 7.2.2. Results: Total of 192 participants was included in this study. (98 in each CML group and apparently healthy population). Mean age of the study population was 47.42 years with 33.67% being females. Physical QoL was significantly poor in CML patients. (p value 0.01) but no difference regarding mental QoL between two groups. Conclusions: Identification of symptom burdens of TKI therapies in routine practice is needed so as to lessen these burdens to effectively improve physical QoL in CML patients. Similarly, for improvement of mental QoL in younger patients (18-39 years’ age group), assessment of psychological impact of the disease and proper counseling in these patients is required. | |
| dc.identifier | https://doi.org/10.70027/jrahs6 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/3954 | |
| dc.language.iso | en_US | |
| dc.publisher | Rapti Academy of Health Sciences (RAHS) | |
| dc.subject | chronic myeloid leukemia (CML) | |
| dc.subject | quality of life (QoL) | |
| dc.subject | tyrosine kinase inhibitors (TKIs) | |
| dc.title | Quality of Life of Chronic Myeloid Leukemia Patients receiving Tyrosine Kinase Inhibitor (TKI): Comparison with Healthy Population | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| oaire.citation.endPage | 16 | |
| oaire.citation.startPage | 11 | |
| relation.isJournalIssueOfPublication | c9fc5c4e-a081-4cb6-a1fa-ae54d38772be | |
| relation.isJournalIssueOfPublication.latestForDiscovery | c9fc5c4e-a081-4cb6-a1fa-ae54d38772be | |
| relation.isJournalOfPublication | 1c0c374c-778e-489d-aca2-4a8949d5bd9a |